Connect with us


Ocular Therapeutix Begins $75M Public Stock Offering

The company makes Dextenza for treatment of inflammation and pain following ophthalmic surgery.




BEDFORD, MA — Ocular Therapeutix Inc., a biopharmaceutical company focused on conditions of the eye, has begun a $75 million public stock offering.

The company’s products include Dextenza, an FDA-approved corticosteroid indicated for the treatment of ocular inflammation and pain following ophthalmic surgery.

The company (Nasdaq: OCUL) is expected to grant the underwriters of the offering a 30-day option to purchase up to an additional $11.25 million of its common stock. All of the shares in the offering are to be sold by the company.

The release notes: “The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.”

Jefferies LLC and Piper Sandler & Co. are acting as joint book-running managers for the offering.

In November 2019, Ocular Therapeutix announced an operational restructuring plan.


The plan was expected to result in about $11 million in annualized savings through personnel reductions and $14 million in “one-time program deferrals,” according to a press release at the time. The company did not say how many jobs would be cut.

With the restructuring, the company is looking to focus resources on Dextenza.




Transform Your Multi-office Phone System Into a Revenue-generation Tool

Weave’s multi-office, multi-department, and multi-provider phone system is built to flexibly accommodate and augment your practices’ most powerful revenue-generation tool: ring phones across multiple locations, set up inter-office call overflow, support external call centers, and more. And by connecting to your patient data, call handlers see a patient’s upcoming appointments, overdue balances, overdue family members, and preferred location – all when they pick up the phone." Learn more at

Promoted Headlines

Most Popular